The chemical class known as LOC100040857 Inhibitors comprises a group of compounds specifically formulated to target and inhibit the activity of the gene product expressed by LOC100040857. This gene, discovered through comprehensive genomic research, is implicated in a variety of cellular processes and plays a pivotal role in certain cellular functions. The activity of LOC100040857 is known to be highly context-sensitive, meaning its functional role can significantly vary depending on the cellular environment and external stimuli. The inhibitors developed for this gene are designed with precision, focusing on selective binding to the proteins or enzymes resulting from LOC100040857 expression. This targeted binding mechanism is crucial as it directly affects the biochemical pathways that involve the LOC100040857 gene product. By modulating the activity of this gene product, these inhibitors aim to alter the corresponding cellular processes, thus influencing specific cellular mechanisms.
The development of LOC100040857 Inhibitors is an intricate and interdisciplinary endeavor, requiring a deep integration of molecular biology, chemistry, and structural biology. To effectively design these inhibitors, a thorough understanding of the structure and function of the LOC100040857 gene product is essential. Techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational molecular modeling are employed to gain a detailed perspective of the target molecule. This comprehensive understanding is pivotal for the rational design of inhibitors that are not only effective in their interaction with the target but also exhibit a high degree of specificity. Typically, these inhibitors are small molecules, crafted to penetrate cellular membranes efficiently and establish a stable and potent interaction with their target. The molecular design of these inhibitors is carefully optimized to ensure robust interactions with the target molecule, usually involving the formation of hydrogen bonds, hydrophobic interactions, and van der Waals forces. The efficacy of these inhibitors is rigorously tested through various biochemical assays in vitro. These assays are critical in assessing the inhibitors' potency, specificity, and overall interaction dynamics, providing key insights into their behavior in controlled experimental conditions. Such studies are crucial for advancing our understanding of the inhibitors' mechanism of action and their potential impact on the intricate network of cellular pathways influenced by LOC100040857.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Rifampicin binds to the beta subunit of RNA polymerase, potentially inhibiting transcription initiation and gene expression. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $166.00 $322.00 | 436 | |
Puromycin causes premature chain termination during mRNA translation, potentially reducing protein synthesis. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Mitomycin C forms DNA crosslinks, potentially inhibiting DNA synthesis and subsequent gene expression. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $275.00 $474.00 $1639.00 $2497.00 $5344.00 | 4 | |
Rocaglamide inhibits translation initiation, which might lead to reduced gene expression at the protein level. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin binds to DNA and inhibits RNA polymerase movement, potentially reducing gene expression. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin inhibits RNA polymerase II, potentially reducing transcription and gene expression. | ||||||
Homoharringtonine | 26833-87-4 | sc-202652 sc-202652A sc-202652B | 1 mg 5 mg 10 mg | $52.00 $125.00 $182.00 | 11 | |
Homoharringtonine inhibits protein translation by blocking the initial steps of protein synthesis. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin interferes with peptide elongation during protein synthesis, potentially reducing gene expression. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin blocks N-linked glycosylation, potentially impacting protein folding and stability. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Geldanamycin binds to Hsp90 and may disrupt its function, potentially affecting the stability and function of client proteins. | ||||||